H.C. Wainwright analyst Robert Burns reiterated a Hold rating on Oric Pharmaceuticals (ORIC – Research Report) today. The company’s shares closed yesterday at $4.59.
According to TipRanks, Burns is an analyst with an average return of -15.8% and a 30.08% success rate. Burns covers the Healthcare sector, focusing on stocks such as BioNTech SE, Portage Biotech Inc, and Springworks Therapeutics.
Oric Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
See the top stocks recommended by analysts >>
Based on Oric Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $23.16 million. In comparison, last year the company had a GAAP net loss of $21.01 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.
Read More on ORIC:
